BeiGene
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
A preliminary analysis of late-stage trial data shows that BeiGene’s investigational checkpoint inhibitor tislelizumab is hitting the mark as a potential first-line treatment in patients with non-squamous non-small cell lung cancer.
The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Here’s a look at the two drugs that had dates this week but were approved early and are now on the market.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.
The drug, a checkpoint inhibitor, met the primary endpoint of improved progression-free survival at the planned interim analysis.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Almost one month after BeiGene’s Bruton’s kinase inhibitor Brukinsa won accelerated approval for mantle cell lymphoma, the company reported the drug failed to hit the mark in a late-stage trial assessing the drug as a treatment for Waldenström’s macroglobulinemia.
JOBS
IN THE PRESS